SANAR BIOTECH CORP.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
BB-101 Innovative Recombinant Protein: Our protein therapy is centered on safety, efficacy, and ethical production. The technology is derived from human thrombomodulin and utilizes an animal-free production system to ensure compliance with the highest standards.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2020
Unified Business No.
83523742
Status
Active
Number of Employees
0
Total Paid-in
Capital
91,500,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Whether you are an investor looking to invest in breakthrough medical solutions, or a channel or technology partner ready to collaborate with us on cutting-edge projects, we sincerely welcome you to join us in jointly driving the future of biomedical innovation. Explore our latest research, where we focus on innovative treatments for androgenetic alopecia. Our team is dedicated to novel protein therapies, combining microneedle technology to promote hair follicle regeneration and provide more effective solutions to improve hair growth outcomes for patients.
(The content above was translated by AI.)
(The content above was translated by AI.)
